Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer
Authors:
Open Access
- 27 July 2012
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 132 (4) , 755-765
Abstract
New approaches are needed to the therapy of advanced prostate cancer. This study determined the effect of growth hormone‐releasing hormone (GHRH) antagonists, JMR‐132 and JV‐1‐38 on growth of PC3 tumors as well as on angiogenesis and metastasis through the evaluation of various factors that contribute largely to the progression of prostate cancer. Human PC3 androgen‐independent prostate cancer cells were injected subcutaneously into nude mice. The treatment with JMR‐132 (10 μg/day) or JV‐1‐38 (20 μg/day) lasted 41 days. We also evaluated the effects of JMR‐132 and JV‐1‐38 on proliferation, cell adhesion and migration in PC‐3 cells in vitro. Several techniques (Western blot, reverse transcription polymerase chain reaction, immunohistochemistry, ELISA and zymography) were used to evaluate the expression levels of GHRH receptors and its splice variants, GHRH, vascular endothelial growth factor (VEGF), hypoxia inducible factor (HIF)‐1α, metalloproteinases (MMPs) −2 and −9, β‐catenin and E‐cadherin. GHRH antagonists suppressed the proliferation of PC‐3 cells in vitro and significantly inhibited growth of PC3 tumors. After treatment with these analogues, we found an increase in expression of GHRH receptor accompanied by a decrease of GHRH levels, a reduction in both VEGF and HIF‐1α expression and in active forms of MMP‐2 and MMP‐9, a significant increase in levels of membrane‐associated β‐catenin and a significant decline in E‐cadherin. These results support that the blockade of GHRH receptors can modulate elements involved in angiogenesis and metastasis. Consequently, GHRH antagonists could be considered as suitable candidates for therapeutic trials in the management of androgen‐independent prostate cancer.Keywords
This publication has 43 references indexed in Scilit:
- Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinasesProceedings of the National Academy of Sciences, 2012
- Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild‐type p53 and decrease in p21 and mutant p53 proteinsThe Prostate, 2011
- The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell linesInternational Journal of Oncology, 2011
- Control of Advanced Cancer: The Road to ChronicityInternational Journal of Environmental Research and Public Health, 2011
- Dose‐dependent growth inhibition in vivo of PC‐3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ‐J‐7‐138The Prostate, 2008
- New Treatment Approaches for Prostate Cancer Based on Peptide AnaloguesEuropean Urology, 2008
- Bone Morphogenetic Protein-6 Promotes Osteoblastic Prostate Cancer Bone Metastases through a Dual MechanismCancer Research, 2005
- Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca 2+ -dependent pathwayProceedings of the National Academy of Sciences, 2005
- Environmental, genetic, and molecular features of prostate cancerThe Lancet Oncology, 2004
- Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10Proceedings of the National Academy of Sciences, 2004